Article
Targeted inhibition of SCF <sup>SKP2</sup> confers anti-tumor activities resulting in a survival benefit in osteosarcoma
2023-05-14
Abstract excerpt
Osteosarcoma(OS) is a highly aggressive bone cancer for which treatment has remained essentially unchanged for decades. Although OS is characterized by extensive genomic heterogeneity and instability, RB1 and TP53 have been shown to be the most commonly inactivated tumor suppressors in OS. We previously generated a mouse model with a double knockout (DKO) of Rb1 and Trp53 within cells of the osteoblastic linea...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ad7aeff9-2933-52a8-b28c-78976c84bc0a
- DOI
- 10.1101/2023.05.13.540637
